AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) A compound of formula (I):



formula (I)

wherein **A** is a group of formula (a) or (b):



(a) (b)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I);

X is O, S, S(O), $S(O)_2$ or NR^{14};

m is 0, 1, 2, 3 or 4;

Y is a group selected from O, NR^5CO, $CONR^5$, $CR^6R^7CONR^5$ and $CR^6R^7NR^5$;

Z is a group selected from $-NR^1R^2$;

$\mathbf{R^1}$ is a group selected from $-COR^8$, $-CONR^8R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

$\mathbf{R^2}$ is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or phosphonooxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^3 is a group selected from hydrogen, halo, cyano, nitro, C_{1-6}alkoxy, C_{1-6}alkyl, $-OR^{12}$, $-CHR^{12}R^{13}$, $-OC(O)R^{12}$, $-C(O)R^{12}$, $-NR^{12}C(O)R^{13}$, $-C(O)NR^{12}R^{13}$, $-NR^{12}SO_2R^{13}$ and $-NR^{12}R^{13}$;
R^4 is hydrogen or a group selected from C_{1-4}alkyl, heteroaryl, heteroarylC_{1-4}alkyl, aryl and arylC_{1-4}alkyl which group is optionally substituted by 1, 2 or 3 substituents selected from halo, methyl, ethyl, cyclopropyl and ethynyl;
R^5 is a group selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;
R^6 and R^7 are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{3-6}cycloalkyl, hydroxy and C_{1-4}alkoxy;
R^8 is C_{1-4}alkyl substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;
R^9 is selected from hydrogen and C_{1-4}alkyl;
R^{10} is selected from hydrogen and C_{1-4}alkyl which C_{1-4}alkyl is optionally substituted by halo, C_{1-4}alkoxy, $S(O)_q$ (where q is 0, 1 or 2) or phosphonooxy;
R^{11}, R^{12}, R^{13} and R^{14} are independently selected from hydrogen, C_{1-4}alkyl and heterocyclyl;
or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Currently amended) A compound according to claim [[2]]1 wherein A is a group of formula (b) as defined in claim 1; or a pharmaceutically acceptable salt thereof.

4. (Previously presented) A compound according to claim 1 wherein X is NH; or a pharmaceutically acceptable salt thereof.

5. (Cancelled)

6. (Previously presented) A compound according to claim 1 wherein R^1 is C_{1-5}alkyl substituted by phosphonooxy and R^2 is hydrogen, C_{1-5}alkyl, C_{2-4}alkynyl or C_{3-6}cycloalkyl; or a pharmaceutically acceptable salt thereof.

7. (Cancelled)

8. (Previously presented) A compound according to claim 1 wherein R^3 is methoxy or hydrogen; or a pharmaceutically acceptable salt thereof.

9. (Previously presented) A compound according to claim 1 wherein R^4 is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro; or a pharmaceutically acceptable salt thereof.

10. (Currently amended) A compound selected from:
3-[(3-{[4-({6-[(3-chlorobenzyl)oxy]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;
3-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3 chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]ethyl dihydrogen phosphate;
2-[ethyl(3-{[4-({6-[(3-fluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3,4-difluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(isopropyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(methyl)amino]ethyl dihydrogen phosphate;
2-[(5-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}pentyl)(ethyl)amino]ethyl dihydrogen phosphate;
4-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]butyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3-fluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(methyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(isobutyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclopropyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclobutyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;

~~2-[(3-[[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclohexyl)amino]ethyl dihydrogen phosphate;~~
~~2-[(3-[[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]ethyl dihydrogen phosphate;~~
~~3-[(3-[[4-({2-[(3-chloro-4-fluorobenzyl)oxy]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;~~
~~2-[(3-[[4-({2-[(3-chlorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(2,2-dimethylpropyl)amino]ethyl dihydrogen phosphate;~~
or a pharmaceutically acceptable salt thereof.

11. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier.

12.-15. (Cancelled)

16. (Withdrawn) A method of treating a human suffering from a disease in which the inhibition of one or more Aurora kinases is beneficial to the treatment, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

17. (Withdrawn) A method of treating a human suffering from colorectal, breast, lung, prostate, pancreatic or bladder and renal cancer or leukemias or lymphomas, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

18. (Currently amended) A process for the preparation of a compound of formula (I) claim 1 or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (II) into a compound of formula (I) by phosphorylation of an appropriate hydroxy group:



formula (II)

where A, X, m, Y, R^3 and R^4 are as defined for formula (I); and **Z'** is a group selected from $-NR^{1'}R^{2'}$; **$R^{1'}$** is a group selected from $-COR^{8'}$, $-CONR^{8'}R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups; **$R^{2'}$** is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or hydroxy, or $R^{2'}$ is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl; and where **$R^{8'}$** is C_{1-4}alkyl substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups:

and thereafter if necessary:

~~i) converting a compound of the formula (I) into another compound of the formula (I); and/or~~

~~ii) removing any protecting groups; and/or~~

[[ii]]i) forming a pharmaceutically acceptable salt thereof.

19. (Withdrawn) The method according to claim 16 wherein Aurora kinase is Aurora-A kinase or Aurora-B kinase.

20. (Previously presented) A compound according to claim 1 wherein **A** is a group of formula (b):



(b)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I);

X is NH;

m is 0, 1, 2, 3 or 4;

Y is a group selected from O, NR^5CO, $CONR^5$, $CR^6R^7CONR^5$ and $CR^6R^7NR^5$;

Z is a group selected from $-NR^1R^2$;

$\mathbf{R^1}$ is a group selected from $-COR^8$, $-CONR^8R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

$\mathbf{R^2}$ is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or phosphonooxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

$\mathbf{R^3}$ is a group selected from hydrogen, halo, cyano, nitro, C_{1-6}alkoxy, C_{1-6}alkyl, $-OR^{12}$, $-CHR^{12}R^{13}$, $-OC(O)R^{12}$, $-C(O)R^{12}$, $-NR^{12}C(O)R^{13}$, $-C(O)NR^{12}R^{13}$, $-NR^{12}SO_2R^{13}$ and $-NR^{12}R^{13}$;

$\mathbf{R^4}$ is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro;

$\mathbf{R^5}$ is a group selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

$\mathbf{R^6}$ and $\mathbf{R^7}$ are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{3-6}cycloalkyl, hydroxy and C_{1-4}alkoxy;

$\mathbf{R^8}$ is C_{1-4}alkyl substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

$\mathbf{R^9}$ is selected from hydrogen and C_{1-4}alkyl;

$\mathbf{R^{10}}$ is selected from hydrogen and C_{1-4}alkyl which C_{1-4}alkyl is optionally substituted by halo, C_{1-4}alkoxy, $S(O)_q$ (where q is 0, 1 or 2) or phosphonooxy;

$\mathbf{R^{11}}$, $\mathbf{R^{12}}$ and $\mathbf{R^{13}}$ are independently selected from hydrogen, C_{1-4}alkyl and heterocyclyl;

or a pharmaceutically acceptable salt thereof.

21. (Currently amended) A compound according to claim 1, wherein:

A is a group of formula (a) or (b):



(a) (b)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I);

X is NH;

m is 0, 1, 2, 3 or 4;

Y is O, NR^5CO or $CR^6R^7NR^5$

Z is $-NR^1R^2$

R^1 is C_{1-5}alkyl substituted by phosphonooxy;

R^2 is a group selected from hydrogen, C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^3 is C_{1-4}alkoxy or hydrogen;

R^4 is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro;

R^5 is hydrogen or methyl; and

R^6 and R^7 are independently hydrogen, fluoro, chloro or methyl;

or a pharmaceutically acceptable salt thereof.

22. (Cancelled)

23. (Previously presented d) A pharmaceutical composition comprising a compound according to claim 10 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier.